Rosen Quoted on Foreign Clinical Trials

24 June 2010 FDA Week News
Foley Partner David Rosen was quoted in an article that appeared in FDA Week on June 24, 2010 titled “OIG, Stakeholders Urge FDA To Clamp Down On Foreign Clinical Trials.” Rosen discusses criticisms directed towards the Food and Drug Administration (FDA) by lawmakers and drug safety advocates for what they view as lackluster oversight of clinical trials conducted abroad. He states that data collected during pivotal trials is likely to come under scrutiny by the FDA, adding that the majority of companies are working hard to ensure that data generated outside the U.S. is of very high quality.

Related Services

Insights

ERISA/Cybersecurity Considerations in the COVID Age
21 October 2020
Privacy, Cybersecurity & Technology Law Perspectives
A Review of Recent Whistleblower Developments
21 October 2020
Legal News: Whistleblower Developments
U.S. EPA Formalizes Reversal of “Once In/Always In” Emission Permitting Policy
21 October 2020
Legal News: Environmental
Georgia Finalizes New Telemedicine Practice Rules
21 October 2020
Health Care Law Today
Discover Telehealth Conference
18 November 2020
Webinar
ACI’s Proficiency Series on Rx Drug Pricing and Rebate Fundamentals
17-19 November 2020
Webinar
2020 NDI Reimagined
11-13 November 2020
Webinar
Foley’s Annual Government Contracts Update
10 November 2020